Evidence map›Paper›PMID 41182407›Full record

ArticleCancer immunology, immunotherapy : CII2025

Increased CD103

Jinsheng Liu, Jintao Zeng, Ting Zhou, Mi Wu, Xiufang Weng

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer immunology, immunotherapy : CII, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. Terminally exhausted CD8Frontiers in immunology · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Jinsheng LiuDepartment of Gastrointestinal Surgery, Shengli Clinical Medical College of Fujian Medical University, Fujian Provincial Hospital, Fuzhou University Affiliated Provincial Hospital, Fuzhou, 350001, Fujian, China.
Jintao ZengDepartment of Colorectal Surgery, the First Affiliated Hospital of Fujian Medical University, Fuzhou, 350005, Fujian, China.
Ting ZhouDepartment of Immunology, School of Basic Medicine, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China.
Mi WuDepartment of Immunology, School of Basic Medicine, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China. wumi0704@126.com.
Xiufang WengDepartment of Immunology, School of Basic Medicine, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China. wengxiufang@hust.edu.cn.

Funding

National Natural Science Foundation of China 32370977
6 · The paper itself

Abstract

While mismatch repair-deficient (dMMR) colorectal cancers (CRCs) exhibit strong immunogenicity and better response to immune checkpoint inhibitors, the more prevalent mismatch repair-proficient (pMMR) CRCs typically show poor T- cell infiltration and inferior outcomes. Profiling the limited tumor-infiltrating CD8

Indexed as

Antigens, CDCD8-Positive T-LymphocytesColorectal NeoplasmsDNA Mismatch RepairIntegrin alpha ChainsLymphocytes, Tumor-InfiltratingAgedFemaleHumansMaleMiddle AgedPhenotypePrognosisTumor Microenvironmentalpha E integrinsAntigens, CDIntegrin alpha ChainsAnti-PD-1treatmentCD103−CD8+ T cellsColorectal cancerTCR clonotypesTPEX phenotype

Identifiers

PMID41182407
PMCPMC12583254

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.